Modeling the response of a biofilm to silver-based antimicrobial

Mathematical Biosciences

Volumn 244, Issue 1, 2013, Pages 29-39

  Stine, A E ^a   Nassar, D ^a   Miller, J K ^a   Clemons, C B ^a   Wilber, J P ^a   Young, G W ^a   Yun, Y H ^a   Cannon, C L ^b   Leid, J G ^c   Youngs, W J ^d   Milsted, A ^d  

^a University of Akron   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c W L GORE AND ASSOCIATES   (United States)

^d UNIVERSITY OF AKRON   (United States)

Author keywords

Antimicrobial; Biofilm modeling; Drug delivery; Nanoparticle; Silver

Indexed keywords

ANTIMICROBIAL; BACTERIAL POPULATION; DRUG DELIVERY SYSTEM; EXTRA-CELLULAR POLYMERIC SUBSTANCES; MINIMUM BACTERICIDAL CONCENTRATION (MBC); PARTICULATE COMPONENTS; PULMONARY INFECTIONS; REACTION DIFFUSION EQUATIONS;

BACTERIA; BIOFILMS; CONTINUUM MECHANICS; DRUG DELIVERY; LINEAR EQUATIONS; MATHEMATICAL MODELS; NANOPARTICLES; NUTRIENTS;

SILVER;

ANTIINFECTIVE AGENT; BIODEGRADABLE POLYMER; NANOPARTICLE; POLYMER; SILVER CARBENE COMPLEX; SILVER DERIVATIVE; UNCLASSIFIED DRUG;

ADVECTION; ANTIMICROBIAL ACTIVITY; AQUEOUS SOLUTION; BIOFILM; DIFFUSION; DRUG; NUMERICAL MODEL; POLYMER; SILVER;

ANTIBACTERIAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BIODEGRADABILITY; BIOFILM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RESPONSE; DRUG TRANSPORT; LUNG; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; MICROBIAL GROWTH; MINIMUM BACTERICIDAL CONCENTRATION; NONHUMAN; NUTRIENT; PREDICTION; REACTION DIFFUSION EQUATION;

ANTI-BACTERIAL AGENTS; BIOFILMS; HUMANS; MODELS, BIOLOGICAL; NANOCAPSULES; POLYMERS; SILVER;

BACTERIA (MICROORGANISMS);

EID: 84878440775     PISSN: 00255564     EISSN: 18793134     Source Type: Journal    
DOI: 10.1016/j.mbs.2013.04.006     Document Type: Article

References (65)

1. Klapper I., Dockery J. Mathematical description of microbial biofilms. SIAM Review 2010, 52(2):221. http://link.aip.org/link/?SIR/52/221/1, 10.1137/080739720.
2. Fux C., Costerton J., Stewart P., Stoodley P. Survival strategies of infectious biofilms. Trends in Microbiology 2005, 13(1):34.
3. Vrany J., Stewart P., Suci P. Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by pseudomonas aeruginosa biofilms displaying rapid-transport characteristics. Antimicrobial Agents and Chemotherapy 1997, 41(6):1352.
4. Chambless J., Hunt S., Stewart P. A three-dimensional computer model of four hypothetical mechanisms protecting biofilms from antimicrobials. Applied and Environmental Microbiology 2006, 72(3):2005.
5. Ramsey B. Drug therapy - management of pulmonary disease in patients with cystic fibrosis. New England Journal of Medicine 1996, 335(3):179. (pMID: 8657217).
6. Lambiase A., Raia V., Pezzo M., Sepe A., Carnovale V., Rossano F. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infectious Diseases 2006, 6(4):1. (pMID: 16405721).
7. Boucher R. New concepts of the pathogenesis of cystic fibrosis lung disease. European Repiratory Journal 2004, 23(1):146.
8. Chmiel J., Konstan M. Anti-inflammatory medications for cysitic fibrosis lung disease: Selecting the most appropriate agent. Treatments in Repiratory Medicine 2005, 4(4):255.
9. Khan T., Wagener J., Bost T., Martinez J., Accurso F., Riches D. Early pulmonary in infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1995, 151(4):1075.
10. Liou T., Adler F., Cox D., Cahill B. Lung transplantation and survival in children with cystic fibrosis. New England Journal of Medicine 2007, 57(21):2143.
11. Kascatan-Nebioglu A., Panzner M.J., Tessier C.A., Cannon C.L., Youngs W.J. N-heterocyclic carbene-silver complexes: a new class of antibiotics. Coordination Chemistry Reviews 2007, 251(5-6):884. http://www.sciencedirect.com/science/article, 10.1016/j.ccr.2006.08.019.
12. Panzner M., Deeraksa A., Smith A., Wright B., Hindi K., Kascatan-Nebioglu A., Torres A., Judy B., Hovis C., Hilliard J., Mallett R., Cope E., Estes D., Cannon C., Leid J., Youngs W. Synthesis and in vitro efficacy studies of silver carbene complexes on biosafety level 3 bacteria. European Journal of Inorganic Chemistry 2009, 13:1739.
13. Kascatan-Nebioglu A., Melaiye A., Hindi K., Durmus S.S., Panzner M., Hogue L., Mallett R., Hovis C., Coughenour M., Crosby S., Milsted A., Ely D.L., Tessier C.A., Cannon C., Youngs W.J. Synthesis from caffeine of a mixed n-heterocyclic carbene-silver complex active against resistant respiratory pathogens. Journal of Medicinal Chemistry 2006, 49(23):6811-6818.
14. Hindi K.M., Ditto A.J., Panzner M.J., Medvetz D.A., Han D.S., Hovis C.E., Hilliard J.K., Taylor J.B., Yun Y.H., Cannon C.L., Youngs W.J. The antimicrobial efficacy of sustained release silver-carbene complex-loaded l-tyrosine polyphosphate nanoparticles: Characterization, in vitro and in vivo studies. Biomaterials 2009, 30(22):3771. http://www.sciencedirect.com/science/article/B6TWB-4W4JR2P-3/2/08c90a705092f78bc2b367c3f4290cfc, 10.1016/j.biomaterials.2009.03.044.
15. Dailey L., Kleemann E., Wittmar M., Gessler T., Schmehl T., Roberts C., Seeger W., Kissel T. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, deapa-pval-g-plga. Pharmaceutical Research 2003, 20:2011.
16. Dailey L., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. Journal of Controlled Release 2003, 86:131.
17. Desai T., Hancock R., Finlay W. A facile method of delivery of liposomes by nebulization. Journal of Controlled Release 2002, 84:69.
18. Kleemann E., Dailey L., Abdelhady H., Gessler T., Schmehl T., Roberts C., Davies M., Seeger W., Kissel T. Modified polyethyleneimines as non-viral gene delivery systems for aerosol gene therapy: investigations of the complex structure and stability during air-jet and ultrasonic nebulization. Journal of Controlled Release 2004, 100:437.
19. Koping-Hoggard M., Issa M., Kohler T., Varum K., Artursson P. A miniaturized nebulization catheter for improved gene delivery to the mouse lung. Journal of Gene Medicine 2005, 7(9):1215.
20. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller G., Prasad B. Poly (dl-lactide-co-glycolide) nanoparticle based inhalable sustained drug delivery system for experimental tuberculosis. Journal of Antimicrobial Chemotherapy 2003, 52:981.
21. Rudolph C., Muller R., Rosenecker J. Jet nebulization of pei/dna polyplexes: physical stability and in vitro gene delivery efficiency. The Journal of Gene Medicine 2002, 4:66.
22. Wong J., Yang H., Blasetti K., Schnell G., Conley J., Schofield L. Liposome delivery of ciprofloxacin against intracellular francisella tularensis infection. Journal of Controlled Release 2003, 92:265.
23. Drury W., Characklis W., Stewart P. Interactions of 1μm latex particles with pseudomonas aeruginos biofilms. Water Research 1993, 27(7):1119.
24. Drury W., Stewart P., Characklis W. Transport of 1μm latex particles in pseudominas aeruginosa biofilms. Biothechnology and Bioengineering 1993, 42:111.
25. Bishop P. Biofilm structure and kinetics. Water Science and Technolgy 1997, 36(1):287.
26. J. Miller, J. Brantner, H. Badawy, P. Wagers, C. Clemons, K. Kreider, A. Milsted, J. Wilber, Y. Yung, W. Youngs, G. Young, Mathematical modeling of pseudomanas aeruginosa biofilm growth and treatment in the cystic fibrosis lung, Mathematical Medicine and Biology in press, http://dx.doi.org.10.1093/imammb/dqt003.
27. Miller J., Neubig R., Clemons C., Kreider K., Wilber J., Young G., Ditto A., Yung Y., Milsted A., Badawy H., Panzner M., Youngs W., Cannon C. Nanoparticle deposition onto biofilms. Annals of Biomedical Engineering 2013, 41:53.
28. Jumbe N., Louie A., Leary R., Liu W., Deziel M., Tam V., Bachhawart R., Freeman C., Kahn J., Bush K., Dudley M., Miller M., Drusano G. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. The Journal of Clinical Investigation 2003, 112(2):275.
29. Anguige K., King J., Ward J. A multi-phase mathematical model of quorum sensing in a maturing pseudomonas aeruginosa biofilm. Mathematical Biosciences 2006, 203(2):240.
30. Wanner O., Reichert P. Mathematical modeling of mixed-culture biofilms. Biotechnology and Bioengineering 1996, 49(2):172.
31. Wanner O., Gujer W. A multispecies biofilm model. Biotechnology and Bioengineering 1986, 28:314.
32. Alpkvist E., Klapper I. A multidimensional multispecies continuum model for heterogeneous biofilm development. Bulletin of Mathematical Biology 2007, 69:765.
33. Eberl H., Morgenroth E., Noguera D., Picioreanu C., Rittmann B., van Loosdrecht M., Wanner O. Mathematical Modeling of Biofilms 2006, IWA Publishing. first ed.
34. Lewis K. Riddle of Biofilm Resistance. Antimicrobial Agents and Chemotherapy 2001, 45(4):999. http://aac.asm.org, 10.1128/AAC.45.4.999-1007.2001.
35. Keren I., Kaldalu N., Spoering A., Wang Y., Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiology Letters 2004, 230(1):13. http://journals.ohiolink.edu/ejc/article.cgi?issn=03781097&issue=v230i0001&article=13pcatta, 10.1016/S0378-1097(03)00856-5.
36. Schumacher M.A., Piro K.M., Xu W., Hansen S., Lewis K., Brennan R.G. Molecular Mechanisms of HipA-Mediated Multidrug Tolerance and Its Neutralization by HipB. Science 2009, 323(5912):396. http://www.sciencemag.org/cgi/content/abstract/323/5912/396, 10.1126/science.1163806.
37. Cogan N. Effects of persister formation on bacterial response to dosing. Journal of Theoretical Biology 2006, 238:694.
38. Wiuff C., Andersson D. Antibiotic treatment in vitro of phenotypically tolerant bacterial populations. Journal of Antimicrobial Chemotherapy 2007, 59:254.
39. Moker N., Dean C., Tao J. Pseudomonas aeruginosa increases formation of multidrug tolerant persister cells in response to quorum-sensing signaling molecules. Journal of Bacteriology 2010, 192:1946.
40. Roberts M., Stewart P. Modeling protection from antimicrobial agents in biofilms through the formation of persister cells. Microbiology-SGM 2005, 151(1):75.
41. Cogan N., Keener J. The role of the biofilm matrix in structural development. Mathematical Medicine and Biology-A Journal of the IMA 2004, 21(2):147.
42. Xavier J., Picioreanu C., Rani S., van Loosdrecht M. Biofilm-control strategies based on enzymic disruption of the extracellular polymeric substance matrix - a modeling study. Microbiology-SGM 2005, 151(12):3817.
43. Alpkvist E., Picioreanu C., van Loosdrecht M., Heyden A. Three-dimensional biofilm model with individual cells and continuum eps matrix. Biotechnology and Bioengineering 2006, 94(5):961.
44. Chopp D., Kristis M., Moran B., Parsek M. The dependence of quorum sensing on the depth of a growing biofilm. Bulletin of Mathematical Biology 2003, 65(6):1053.
45. Laspidou C., Rittmann B. Modeling the development of biofilm density including active bacteria, inert biomass, and extracellular polymeric substances. Water Research 2004, 38:3349.
46. Frederick M., Kuttler C., Hense B., Eberl H. A mathematical model of quorum sensing regulated eps production in biofilm communities. Theoretical Biology and Medical Modeling 2011, 8(8):1.
47. Szomolay B., Klapper I., Dockery J., Stewart P. Adaptive responses to antimicrobial agents in biofilms. Environmental Microbiology 2005, 7(8):1186.
48. Dodds M., Grobe K., Stewart P. Modeling biofilm antimicrobial resistance. Biotechnology and Bioengineering 2000, 68(4):456.
49. Cogan N., Cortez R., Fauci L. Modeling physiological resistance in bacterial biofilms. Bulletin of Mathematical Biology 2005, 67(4):831.
50. D. Paul, F. Haris (Eds.), Controlled Release from Erodible Slabs, Cylinders, and Spheres, American Chemical Society:Washington D.C., 1976.
51. Hopfenberg H. Controlled release from erodible slabs, cylinders, and spheres. Controlled Release Polymeric Formulations ACS Symposium Series 1976, 33:27.
52. J.G. Leid, Personal, Communication (2009).
53. Stewart P.S. Biofilm accumulation model that predicts antibiotic resistance of pseudomonas-aeruginosa biofilms. Antimicrobial Agents and Chemotherapy 1994, 38(5):1052.
54. Reichert P., Wanner O. Movement of solids in biofilms: significance of liquid phase transport. Water Science Technology 1997, 36(1):321.
55. Hombreiro-Pérez M., Siepmann J., Zinutti C., Lamprecht A., Ubrich N., Hoffman M., Bodmeier R., Maincent P. Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release. Journal of Controlled Release 2003, 88:413.
56. Picioreanu C., Kreft J., van Loosdrecht M. Particle based multidimensional multispecies biofilm model. Applied and Environmental Microbiology 2004, 70(5):3024.
57. Guyer J.E., Wheeler D., Warren J.A. FiPy: partial differential equations with python. Computing in Science & Engineering 2009, 11:6.
58. D. Nassar, A mathematical model of biofilm growth and decay, 2009, The Univeristy of Akron, Master's thesis.
59. Borriello G., Richards L., Ehrlich G., Stewart P. Arginine or nitrate enhances antibiotic susceptibility of pseudomonas aeruginosa in biofilms. Antimicobial Agents and Chemotherapy 2006, 50(1):382.
60. Rybak M. Pharmacodynamics: relation to antimicrobial resistance. American Jounal of Medicine 2006, 119(6):S37.
61. Dörr T., Vulić M., Lewis K. Ciprofloxacin causes persister formation by inducing the tisb toxin in escherichia coli. PLoS Biol 2010, 8(2):e1000317. 10.1371/journal.pbio.1000317.
62. Dörr T., Lewis K., Vulić M. Sos response induces persistence to fluoroquinolones in escherichia coli. PLoS Genet 2009, 5(12):e1000760. 10.1371/journal.pgen.1000760.
63. Xavier J., Picioreanu C., Rani S., van Loosdrecht M., Stewart P. Biofilm-control strategies based on enzymic disruption of the extracellular polymeric substance matrix - a modeling study. Microbiology 2005, 151(12):3817.
64. Cogan N., Cortez R., Fauci L. Modeling physiological resistance in bacterial biofilms. Bulletin of Mathematical Biology 2005, 67(4):831.
65. Roberts M., Stewart P. Modeling protection from anticrobial agents in biofilms through the formation of persister cells. Microbiology 2005, 151(1):75.